The European Association of Urology and Elsevier are proud to present URO ONCO, the online educational platform for all healthcare professionals in uro-oncology.
URO ONCO provides up-to-date information on developments in the field of urological malignancies. With urological tumours presenting three of the ten most commonly found cancers, the need for up-to-date cancer management knowledge is essential for urologists
- Selected meeting abstracts - including editorial comment
- Expert interviews on a range of Uro-oncology topics including
- News reports from the ASCO Annual meeting
- Related ASCO 2017 resources
Interviews from EAU 2017, London, UK, 24 – 28 March 2017
Latest Headlines in Prostate
Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series
European Urology, Volume 71, Issue 6, June 2017, Pages 886 - 893
Editorial comment from Piotr Chlosta: In this multi-institutional restrospective comparison of adjuvant (aRT) versus observation and early salvage radiation therapy (esRT) in pT3N0 prostate cancer patients, no significant differences in metastatic free survival and overall survival were observed. Results suggest that esRT may potentially reduce overtreatment without compromising cancer control.
A Specific Mapping Study Using Fluorescence Sentinel Lymph Node Detection in Patients with Intermediate- and High-risk Prostate Cancer Undergoing Extended Pelvic Lymph Node Dissection
European Urology, Volume 70, Issue 5, November 2016, Pages 734 - 737
Editorial comment from Piotr Chlosta: Low sensitivity of indocyanine green (ICG) for the detection of lymph node metastases reported in our study highlight the difficulties related to the implementation of SNL techniques in prostate cancer. Drainage pattern is complex, lymph node metastases in PCa do not follow a predefined pathway of metastatic spread and that the sentinel node technique does not represent an alternative to an extended pelvic LND.
Why and Where do We Miss Significant Prostate Cancer with Multi-parametric Magnetic Resonance Imaging followed by Magnetic Resonance-guided and Transrectal Ultrasound-guided Biopsy in Biopsy-naïve Men?
European Urology, Volume 71, Issue 6, June 2017, Pages 896 - 903
Editorial comment from Piotr Chlosta: Study demonstrated that systematic and MRI-targeted biopsy miss clinically significant prostate cancer in different areas of the prostate gland. Systematic TRUS biopsy most commonly missed csPCa in anterior prostate, while MRI-targeted biopsy in dorsolateral area of the gland, whereas both techniques have difficulties in detecting apical lesions. These results may help in biopsy planning.
Latest Headlines in Bladder
Early Recurrence Patterns Following Totally Intracorporeal Robot-assisted Radical Cystectomy: Results from the EAU Robotic Urology Section (ERUS) Scientific Working Group
European Urology, Volume 71, Issue 5, May 2017, Pages 723 - 726
Editorial comment from Piotr Chlosta: Retrospective analysis of early recurrences in 717 patients undergoing totally intracorporeal robot-assisted radical cystectomy (RARC) in nine centers showed recurrence patterns similar to those reported for open radical cystectomy series.
Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study
Kavalieris L, O'Sullivan P, Frampton C, Guilford P, Darling D, Jacobson E et al.J Urol. 2017 Jun;197(6):1419-1426.
Editorial comment from Piotr Chlosta:
A novel noninvasive multigene urine biomarker test for the surveillance of bladder cancer recurrence, The Cxbladder Monitor, offers high sensitivity and high negative predictive value for ruling out urothelial carcinoma. Results suggest potential for deferring or avoiding cystoscopy in bladder cancer patients.
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, et al.Lancet Oncol. 2017 Mar;18(3):312-322.
Editorial comment from Piotr Chlosta: In patients with metastatic or surgically unresectable advanced urothelial carcinoma with progression or recurrent disease despite first line platinum-based chemotherapy, PD-1 inhibitor nivolumab monotherapy was associated with meaningful clinical benefit, regardless of PD-L1 expression.
Latest Headlines in Kidney
Cryoablation versus Partial Nephrectomy for Clinical T1b Renal Tumors: A Matched Group Comparative Analysis
European Urology, Volume 71, Issue 1, January 2017, Pages 111 - 117
Editorial comment from Piotr Chlosta: Patients treated with cryoablation(CA) for cT1b renal tumors had a significantly higher rate of local cancer recurrence at 1 year compared to those treated with partial nephrectomy (PN). The authors found a higher but not significantly different postoperative complication rate for the PN group, a significantly higher local recurrence rate for the CA group, and similar overall and cancer-specific survival. The role of CA for cT1b RCC need to be determined.
Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial
Haas NB, Manola J, Dutcher JP, Flaherty KT, Uzzo RG, Atkins MB, et al.JAMA Oncol. 2017 Mar 9. [Epub ahead of print]
Editorial comment from Piotr Chlosta: Analysis of data from ASSURE trial showed that adjuvant treatment with sunitinib or sorafenib did not improve disease-free survival in high-risk subset of patients with clear cell RCC.
Impact of antibiotics on outcome in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors
L. Derosa, B. Routy, D. Enot, G. Baciarello, C. Massard, Y. Loriot, et al.J Clin Oncol 35, 2017 (Suppl 6S; abstract 462)
Editorial comment from Prof. Piotr Chlosta:
This retrospective analysis suggests efficacy of immunotherapy may be lower in patients receiving antibiotic less than a month before starting treatment. Relationship between the gut microbiome and response to immunotherapy should be further investigated.
Editor’s Introduction to URO ONCO
Interviews from EAU 2017, London, UK – 24 – 28 March 2017
EAU 2017 Scientific Programme and Sessions
View the Scientific Programme and Sessions of the 2017 EAU Annual Congress, Munich, Germany.
5 most popular articles
- Jun 201728Jun 201730
ISSECAMConvento do BeatoLisbon, Portugal
- Jun 201728Jun 201729
Anthias Consultancy LtdThe Open UniversityMilton Keynes, United Kingdom
- Jul 201714Jul 201715
European Society for Translational Medicine (EUSTM)ViennaVienna, Austria